Radioimmunoassay for detection of anti-oligodendrocyte antibodies.

New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology (1995) 8.63

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 4.27

Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol (1992) 3.53

Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture. Nature (1978) 3.29

Recall of early menstrual history and menarcheal body size: after 30 years, how well do women remember? Am J Epidemiol (2002) 3.11

Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science (1991) 2.77

Host defenses in experimental scrub typhus: role of cellular immunity in heterologous protection. Infect Immun (1976) 2.60

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology (1998) 2.52

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 2.19

Long-term body-weight-supported treadmill training and subsequent follow-up in persons with chronic SCI: effects on functional walking ability and measures of subjective well-being. Spinal Cord (2005) 2.18

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 2.06

Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05

Postexercise net protein synthesis in human muscle from orally administered amino acids. Am J Physiol (1999) 2.00

Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature (1987) 1.99

Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85

Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol (1977) 1.84

Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.80

Schistosomiasis in the congenitally athymic (nude) mouse. I. Thymic dependency of eosinophilia, granuloma formation, and host morbidity. J Immunol (1977) 1.68

Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. J Immunol (1990) 1.67

Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66

Muscular dystrophy in young girls. Neurology (1970) 1.60

Isolated testicular vasculitis mimicking a testicular neoplasm. J Clin Pathol (1994) 1.59

Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59

Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res (1995) 1.57

MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. J Neuroimmunol (1987) 1.57

In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57

Thallium poisoning. Arch Neurol (1972) 1.52

Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50

The thymus in myasthenia gravis. Evidence for altered cell populations. N Engl J Med (1974) 1.50

Cell type-specific markers for human glial and neuronal cells in culture. Lab Invest (1980) 1.49

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48

Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46

Perivascular location and phenotypic heterogeneity of microglial cells in the rat brain. J Neuroimmunol (1990) 1.45

Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis. Ann Neurol (1992) 1.44

High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43

Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43

An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol (2001) 1.41

Lack of hemispheric localizing value of the palmomental reflex. Neurology (2005) 1.40

Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol (1998) 1.40

Immunologic aspects of host responses to schistosomiasis: resistance, immunopathology, and eosinophil involvement. Prog Allergy (1978) 1.39

Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol (1998) 1.39

Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. J Neurol Sci (1996) 1.38

Axonal transport of proteins in experimental neuropathies. Science (1969) 1.36

Cell-mediated immunity to myelin basic protein in acute disseminated encephalomyelitis. Neurology (1974) 1.35

Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J Immunol (1999) 1.35

N-methyl-D-aspartate receptors expressed in a nonneuronal cell line mediate subunit-specific increases in free intracellular calcium. J Biol Chem (1997) 1.32

Delayed hypersensitivity granuloma formation and modulation around Schistosoma mansoni eggs in vitro. II. Regulatory T cell subsets. J Immunol (1982) 1.31

Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes. Science (1986) 1.31

Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology (1986) 1.29

Tropical diseases of importance to the traveler. Adv Intern Med (1984) 1.28

Induction of mouse type-C RNA virus by lipopolysaccharide. J Immunol (1975) 1.28

Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle. Immunology (1990) 1.27

Experimental allergic neuritis induced by sensitization with galactocerebroside. Science (1979) 1.26

Body weight supported treadmill training in acute spinal cord injury: impact on muscle and bone. Spinal Cord (2005) 1.26

Multiple sclerosis and Sjögren's syndrome: a problem in diagnosis or in definition of two disorders of unknown etiology? Ann Neurol (1990) 1.26

In vivo demyelination induced by intraneural injection of anti-galactocerebroside serum: a morphologic study. Am J Pathol (1979) 1.25

Active suppression as a possible mechanism of tolerance in tetraparental mice. J Exp Med (1973) 1.25

Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism. J Physiol (2013) 1.25

Antiserum-mediated demyelination in vivo: a sequential study using intraneural injection of experimental allergic neuritis serum. Lab Invest (1978) 1.25

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23

Transfer of demyelination by intraneural injection of experimental allergic neuritis serum. Nature (1978) 1.23

Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol (1983) 1.23

Cell-mediated immunity in interstitial nephritis. III. T lymphocyte-mediated fibroblast proliferation and collagen synthesis: an immune mechanism for renal fibrogenesis. J Immunol (1980) 1.22

Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22

Cellular adaptation to repeated eccentric exercise-induced muscle damage. J Appl Physiol (1985) (2001) 1.22

The prognosis of acute polyradiculoneuritis. Neurology (1968) 1.22

Familial proximal spinal muscular atrophy. Arch Neurol (1966) 1.21

Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol (1986) 1.20

Limiting dilution analysis of the frequency of antigen-reactive lymphocytes isolated from the central nervous system of Lewis rats with experimental allergic encephalomyelitis. Cell Immunol (1987) 1.20

Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20

Dissociation of antibody production from disease suppression in the inhibition of allergic encephalomyelitis by myelin basic protein. J Immunol (1970) 1.19

Tissue culture analysis of neurogenesis: myelination and synapse formation are retarded by serum deprivation. Brain Res (1978) 1.19

Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology (1988) 1.18

Delayed hypersensitivity to encephalitogenic protein in disseminated encephalomyelitis. Lancet (1968) 1.17

Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice. Brain (2005) 1.16

Inosiplex in the treatment of subacute sclerosing panencephalitis. Arch Neurol (1979) 1.16

Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol (1984) 1.16

Guillain-Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology (1985) 1.16

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15

Onion bulb neuropathies. Arch Neurol (1972) 1.15

Circulating immune complexes in multiple sclerosis and other neurological diseases. Lancet (1976) 1.14

Lymphokine modulation of fibroblast proliferation. J Immunol (1982) 1.14

Fibroblast growth factor is a mitogen for oligodendrocytes in vitro. Brain Res (1985) 1.13

Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13

Hyperkalemic periodic paralysis and cardiac arrhythmia. Neurology (1972) 1.13

Cellular immunity in the mouse. II. Correlation of in vivo and in vitro phenomena. Cell Immunol (1972) 1.12

Murine interstitial nephritis. I. Analysis of disease susceptibility and its relationship of pleiomorphic gene products defining both immune-response genes and a restrictive requirement for cytotoxic T cells at H-2K. J Exp Med (1982) 1.12

Cell-mediated immunity in interstitial nephritis. I. T lymphocyte systems in nephritic guinea pigs: the natural history and diversity of the immune response. J Immunol (1979) 1.12

Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol (2001) 1.11

Coronavirus mouse hepatitis virus (MHV)-A59 causes a persistent, productive infection in primary glial cell cultures. Microb Pathog (1987) 1.11

Delayed hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro. I. Definition of the model. J Immunol (1982) 1.11

Cellular immunity in the mouse. I. In vitro lymphocyte reactivity. Cell Immunol (1972) 1.10

Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10